Biomarkers of cell death applicable to early clinical trials

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Emerging anticancer drugs target apoptosis and survival pathways, necessitating methods to monitor their clinical impact.
• Biomarkers of cell death are crucial for assessing tumor biology and drug response in cancer patients.
• The development of predictive biomarkers alongside novel drugs aims to streamline drug development and reduce attrition rates.

Purpose of the Study:

• To review the challenges and recent advances in the development and application of cell death biomarkers.
• To explore the utility of biomarkers in preclinical and early clinical trials for novel anticancer drugs.
• To discuss the validation, deployment, interpretation, and clinical utility of cell death biomarkers.

Main Methods:

• Review of literature on biomarkers of apoptosis and cell death in cancer drug development.
• Exploration of challenges in biomarker validation, deployment, and interpretation.
• Examination of advances in using biomarkers in preclinical and early clinical trial settings.

Main Results:

• Tumor biopsies are ideal for apoptosis measurement, but less invasive biomarkers (blood, imaging) are clinically preferred.
• Biomarkers are essential for the pharmacological audit trail, accelerating novel drug development.
• Significant challenges exist in validating and implementing cell death biomarkers in clinical practice.

Conclusions:

• Effective monitoring of novel apoptosis-targeting drugs requires robust cell death biomarkers.
• Overcoming challenges in biomarker validation and clinical integration is key to successful cancer drug development.
• Biomarkers play a vital role in expediting the evaluation of new cancer therapies that induce tumor cell death.